Company / Operating Cash Flow per Share
ALNYLAM PHARMACEUTICALS, INC. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
$4.05
FY2025
5-year range
-$5.12 / $4.05
FY2021-FY2025
Trend
+6234.4%
vs FY2024
Sector context
#28 of 212
Health Care
What the data says
Operating Cash Flow per Share changed +6234% YoY in FY2025, a notable deviation from the 9-year average annual change of +682%.
Based on SEC 10-K filings.
4.05 in FY2025. Top quartile in the Health Care sector.
Improved from $0.84 to $4.05 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 13% in Health CareTop 13% of 212This company $4.05 Sector average $5.28
▼
-23.2% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 6234.4% year-over-year.
- Ranks #28 out of 212 companies in the Health Care sector.
- Lowest operating cash flow per share in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.37 (distress zone, below 1.8 threshold)
- Negative profit margin: -12.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.05 | +6234.4% |
| FY2024 | -$0.07 | -107.9% |
| FY2023 | $0.84 | +116.4% |
| FY2022 | -$5.12 | -114.0% |
| FY2021 | -$2.39 | +52.3% |
| FY2020 | -$5.01 | -32.6% |
| FY2019 | -$3.78 | -22.5% |
| FY2018 | -$3.09 | +27.0% |
| FY2017 | -$4.23 | -17.6% |
| FY2016 | -$3.59 | -59.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026